TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03597581

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab is a vascular endothelial growth factor inhibitor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab is a vascular endothelial growth factor inhibitor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX regimen
Description: The FOLFOX regimen used for this protocol consists of oxaliplatin given at 85 mg/m2 IV together with leucovorin at 400 mg/m2 IV (substitution with levo-leucovorin 200 mg/m2 IV is allowed) (duration per institutional policy), followed by a 5-FU bolus of 400 mg/m2 (over 2-5 minutes), and then continuous infusional 5-FU given at a dose of 2400 mg/m2 over 46-48 hours (1200 mg/m2/day), given on Days 1 and 15 of each 28-day cycle. A minimum of 8 FOLFOX cycles should be received if tolerated per standard of care guidelines

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX regimen
Description: The FOLFOX regimen used for this protocol consists of oxaliplatin given at 85 mg/m2 IV together with leucovorin at 400 mg/m2 IV (substitution with levo-leucovorin 200 mg/m2 IV is allowed) (duration per institutional policy), followed by a 5-FU bolus of 400 mg/m2 (over 2-5 minutes), and then continuous infusional 5-FU given at a dose of 2400 mg/m2 over 46-48 hours (1200 mg/m2/day), given on Days 1 and 15 of each 28-day cycle. A minimum of 8 FOLFOX cycles should be received if tolerated per standard of care guidelines
Study: NCT03575065

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-290
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-290
Description: Administered orally
Study: NCT01054560

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SOLITAIRE™ Device
Description: The SOLITAIRE™ Device is the experimental device that will be used in the interventional procedure

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MERCI® Device
Description: The MERCI® Device is the control device that will be used in the interventional procedure.
Study: NCT01964781

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adrenaline
Description: Topical adrenaline - does it reduce bleeding on its own, and does it enhance the effect of tranexamic acid?
Study: NCT01117298

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadalafil
Description: Tab Tadalafil, 20 mg alternate day for 8 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tab Placebo every alternate day for 8 weeks
Study: NCT05213637

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Expanded Activated Lymphocytes (EAL)
Description: 12\~20 doses of EAL (1×10\^9\~2×10\^10 cells per dose) will be infused into patients.
Study: NCT03584516

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itacitinib
Description: In Part 1dose determination participants will receive itacitinib administered orally once daily at the protocol-defined dose according to cohort enrollment. In Part 1 expansion, participants will receive either itacitinib administered orally either once daily or twice a day or corticosteroid alone based on the assigned treatment regimen according to cohort enrollment. In Part 2, participants will receive the recommended dose from Part 1 expansion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itacitinib
Description: In Part 1dose determination participants will receive itacitinib administered orally once daily at the protocol-defined dose according to cohort enrollment. In Part 1 expansion, participants will receive either itacitinib administered orally either once daily or twice a day or corticosteroid alone based on the assigned treatment regimen according to cohort enrollment. In Part 2, participants will receive the recommended dose from Part 1 expansion.
Study: NCT05213637

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: transarterial chemoembolization (TACE)
Description: After angiography, fluorouracil will be injected into the proper hepatic artery or the segment of liver where the original lesion is located, and then microcatheter will be introduced into the segment of liver artery where the incision margin is located, and iodized oil injection and epirubicin will be mixed and embolized.
Study: NCT03584516

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Itacitinib
Description: In Part 1dose determination participants will receive itacitinib administered orally once daily at the protocol-defined dose according to cohort enrollment. In Part 1 expansion, participants will receive either itacitinib administered orally either once daily or twice a day or corticosteroid alone based on the assigned treatment regimen according to cohort enrollment. In Part 2, participants will receive the recommended dose from Part 1 expansion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: In Part 2, participants will receive matching placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Administered in Parts 1 and 2 as background reference therapy at a dose level that is commensurate with institutional guidelines based on organ involvement and severity of disease.
Study: NCT05213637

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transarterial chemoembolization (TACE)
Description: After angiography, fluorouracil will be injected into the proper hepatic artery or the segment of liver where the original lesion is located, and then microcatheter will be introduced into the segment of liver artery where the incision margin is located, and iodized oil injection and epirubicin will be mixed and embolized.
Study: NCT03589989

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ENDS (vaporizer/e-cig) and smoking cessation counseling
Description: Participants in the intervention group will receive an ENDS and nicotine-containing e-liquids, which they will be allowed to use ad libitum. Additionally, they will receive smoking cessation counseling. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 6-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6 months, participants will be asked to come to a final clinical visit.
Study: NCT03584516

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Administered in Parts 1 and 2 as background reference therapy at a dose level that is commensurate with institutional guidelines based on organ involvement and severity of disease.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methylprednisolone
Description: Administered in Parts 1 and 2 as background reference therapy at a dose level that is commensurate with institutional guidelines based on organ involvement and severity of disease.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Administered in Parts 1 and 2 as background reference therapy at a dose level that is commensurate with institutional guidelines based on organ involvement and severity of disease.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Administered in Parts 1 and 2 as background reference therapy at a dose level that is commensurate with institutional guidelines based on organ involvement and severity of disease.
Study: NCT03589989

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Smoking cessation counseling
Description: Participants in the control group will receive smoking cessation counseling only. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 6-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6 months, participants will be asked to come to a final clinical visit.
Study: NCT01532076

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cellularized composite graft augmentation
Description: liposuction, cell isolation, embedding of SVF cells in fibrin gel, wrapping around hydroxyapatite granules

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Acellular composite graft augmentation
Description: Open reduction and internal fixation using acellular augmentation with fibrin embedded granulated hydroxyapatite
Study: NCT01618435

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: i-FACTOR
Description: i-FACTOR mixed with autologous bone from the decompression placed in the operation site for enhancing fusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: i-FACTOR
Description: i-FACTOR mixed with autologous bone from the decompression placed in the operation site for enhancing fusion
Study: NCT01877850

Intervention type: PROCEDURE
Intervention: weaning protocol
Description: Reduction of pressure support ventilation (PSV) by 2cmH2O at a time to a maximum of 4cmH2O per day.~When a patient was able to tolerate PSV less than 8 cmH2O for at least 120 minutes, the nurses started to reduce End Expiratory Positive Pressure (PEEP) by 2cmH2O at a time to a maximum of 4cmH2O per day.~When a patient was able to tolerate PSV less than 8 cmH2O with PEEP less than 6 cmH2O, the nurses started SBT trial: Continuos Positive Pressure Airways of 6cmH2O for at least 120 minutes and following discontinuation from ventilator.
Study: NCT02806219

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Prefilled syringe (PFS)
Description: Active substance: Certolizumab Pegol Pharmaceutical form: Solution for injection Administration: By prefilled syringe (PFS)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: e-Device
Description: Active substance: Certolizumab Pegol Pharmaceutical form: Solution for injection Administration: By e-Device
Study: NCT04109794

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: E-CTG
Description: Envelope connective tissue graft

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: E-CTG
Description: Envelope connective tissue graft
Study: NCT01964781

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: tranexamic acid plus saline

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline
Study: NCT01643538

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial incentive
Description: Participants will receive a direct financial incentive in the amount of $20 for each week when their daily pedometer step count equals or exceeds their goal at least 5 out of 7 days.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Goal
Description: Participants will be asked to identify a charity to which they would like to donate the payment for reaching their walking goal. Each week they will be asked to designate which charity should receive a donation if they meet or exceed their goal. If they meet the goal, they will be notified that a donation of $20 in their name has been sent to the charity.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personal financial incentives & social goals
Description: Participants will be able to allocate their reward for reaching their walking goal: the $20 reward can be divided between personal financial incentive and a charitable donation. Each week, the participant will be asked to choose whether to keep, give, or split the reward, if they meet or exceed their goal. If they choose to send some of the money to charity, they will be asked to identify a charity to which they would like to donate the payment. If they meet their goal, they will be notified by email or mail (based on their preference), that a donation of the selected amount has been sent to the charity.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: daily pedometer use and weekly feedback
Description: Daily use of pedometer for 5 months. Walking goal set based on level of walking during 2-week run-in period. Weekly feedback provided on meeting walking goal - defined as achieving goal number of steps for 5 of 7 days per week.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: daily pedometer use and weekly feedback
Description: Daily use of pedometer for 5 months. Walking goal set based on level of walking during 2-week run-in period. Weekly feedback provided on meeting walking goal - defined as achieving goal number of steps for 5 of 7 days per week.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: daily pedometer use and weekly feedback
Description: Daily use of pedometer for 5 months. Walking goal set based on level of walking during 2-week run-in period. Weekly feedback provided on meeting walking goal - defined as achieving goal number of steps for 5 of 7 days per week.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: daily pedometer use and weekly feedback
Description: Daily use of pedometer for 5 months. Walking goal set based on level of walking during 2-week run-in period. Weekly feedback provided on meeting walking goal - defined as achieving goal number of steps for 5 of 7 days per week.
Study: NCT03414645

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAM-101 10%
Description: fibrinogen-depleted human platelet lysate

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Control
Description: PlasmaLyte-A, vehicle control, a preservative-free ophthalmic drop

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAM-101 30%
Description: fibrinogen-depleted human platelet lysate
Study: NCT01211184

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Water administration
Description: patients undergo hip surgery after receiving 800 ml water by mouth in the morning before the surgery.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: carbohydrate drink
Description: 800 ml carbohydrate drink by mouth the evening before surgery and 400 ml carbohydrate drink by mouth 2 hours before surgery

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Fasting.
Description: The patient is fasting from midnight before the surgery.
Study: NCT03865875

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Program
Description: Participants will start the exercise program within 2 weeks of enrollment and will continue until surgery. This program will consist of twice weekly individualized sessions with a trainer.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition Program
Description: Each patient enrolled will undergo nutritional assessment at their initial post-enrollment visit to develop an individualized nutrition plan to be implemented up until when the patient undergoes surgery.
Study: NCT01759862

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aminophylline
Description: Aminophylline loading dose 5mg/kg prior to transplant and will continue to receive aminophylline 1.8mg/kg Q6h for a total of 20 doses.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Theophylline drug levels
Description: Theophylline drug levels will be monitored every morning from all patients for the first 4 days post- transplant.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Theophylline drug levels
Description: Theophylline drug levels will be monitored every morning from all patients for the first 4 days post- transplant.
Study: NCT03584516

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisone
Description: Administered in Parts 1 and 2 as background reference therapy at a dose level that is commensurate with institutional guidelines based on organ involvement and severity of disease.
Study: NCT04500301

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preemptive Pharmacogenomic Testing
Description: The use of a pharmacogenomic (PGx) testing to help manage drugs prescribed to subjects for pain and depression.
Study: NCT01759862

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will receive placebo infusion of normal saline, pre-transplant, followed by normal saline infusions matched by volume and frequency to treatment arm for a total of 20 doses.
Study: NCT01324310

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romidepsin
Description: Romidepsin 8 mg/m\^2 intravenous infused over 4 hours on Day 1 and Day 8.
Study: NCT04030169

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midomafetamine HCl
Description: Non-directive psychotherapy conducted during MDMA-assisted psychotherapy session
Study: NCT00830557

Intervention type: OTHER
Intervention: medical chart review
Description: baseline, 12 month and 36 months

Intervention type: OTHER
Intervention: survey administration
Description: baseline, 6 month, 12 month

Intervention type: OTHER
Intervention: biospecimen collection
Description: baseline
Study: NCT03684109

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3T MRI Scanner
Description: 3T MRI Scanner providing Mega-laser sequence for single-voxel Magnetic Resonance Spectroscopy (MRS) data for 2 hydroxyglutarate (2HG) quantitation.
Study: NCT00630929

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: 800 mg oral tablet 3 times daily with meals for 6 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched placebo orally for 6 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: 200 mg oral capsule once daily with morning meal for 6 weeks
Study: NCT04475653

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Physical Activity using an Activity Tracker

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical Activity using an Activity Tracker

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical Activity using an Activity Tracker
Study: NCT01324310

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoconazole
Description: Ketoconazole 400 mg oral once daily on Days 4-8
Study: NCT02040363

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Muscular biopsy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Muscular biopsy

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Muscular biopsy

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 5-10 weeks sport training
Study: NCT03032705

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SonicFill™ 2
Description: The intervention in arm 1 is SonicFill™ 2, a sonic-activated, bulk fill dental composite system for posterior restorations that requires no additional capping layer.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Filtek™ Supreme
Description: The intervention in arm 2 is Filtek™ Supreme Ultra, a Universal Nanocomposite dental restorative material that is visible-light activated and designed for use in anterior and posterior restorations of any class.
Study: NCT04635943

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ivermectin
Description: One daily dose of NOXAL-Ivermectin Oral Solution (6 mg/mL) at 300mcg/kg for three (3) consecutive days. A weight-equivalence table will be used to determine each participant´s dose (number of oral drops/day).
Study: NCT00729573

Intervention type: DRUG
Intervention: Emtricitabine/tenofovir disoproxil fumarate
Description: 200 mg/300 mg tabletas a part of MTN-003

Intervention type: DRUG
Intervention: Emtricitabine/tenofovir disoproxil fumarate placebo
Description: placebo tablet as a part of MTN-003

Intervention type: DRUG
Intervention: Tenofovir disoproxil fumarate
Description: 300 mg tablet as a part of MTN-003

Intervention type: DRUG
Intervention: Tenofovir disoproxil fumarate placebo
Description: placebo tablet as a part of MTN-003
Study: NCT02796794

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Genistein
Description: Total 30 patients will be included into the study They will be divided into two groups each containing 15 patients. Intervention group will receive supplemental genistein (60 mg/day) to enteral nutrition

Intervention type: OTHER
Group type: OTHER
Intervention: enteral nutrition only
Description: These are the patients receiving enteral nutrition
Study: NCT00919854

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darunavir
Description: Darunavir oral suspension (100 mg/mL) will be administered as 20 mg per kg body weight twice daily for children weighing between 10 and \<20 kg before dose adjustment. Darunavir oral suspension will be administered 25 mg per kg body weight twice daily if weight less than 15 kg, and fixed dose of 375 mg darunavir tablets twice daily if weight more than or equal to 15 kg after dose adjustment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: Ritonavir oral solution (80 mg/mL) will be administered as 3 mg per kg body weight twice daily before dose adjustment and after dose adjustment fixed dose of 50 mg twice daily if weight more than or equal to 15 kg.
Study: NCT02573844

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Proklama

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01138982

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Youth Mentoring program
Study: NCT04635527

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI318
Description: before surgery IBI318 intravenous injection Q2W,after surgery IBI318 intravenous injection Q4W

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cTACE
Description: conventional transarterial chemoembolization
Study: NCT04060212

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tuna fish
Description: Six meals of tunafish (\~200gms) will be consumed. Three meals will be consumed in a period of 14 days, and a subsequent 3 meals will be consumed within a 14 day period six month after the first 3 meals.
Study: NCT04635527

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: cTACE
Description: conventional transarterial chemoembolization

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: before surgery placebo intravenous injection Q2W,after surgery placebo intravenous injection Q4W
Study: NCT04855149

Intervention type: OTHER
Intervention: Patient satisfaction
Description: Patient satisfaction evaluated with EVAN LR questionnaire

Intervention type: OTHER
Intervention: Patient satisfaction
Description: Patient satisfaction evaluated with EVAN LR questionnaire
Study: NCT04147429

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early Literacy Intervention
Description: Similar to the standard Reach out and Read model, parents will be given a high-contrast board book, Cluck and Moo, and education about the importance of and how to engage with newborns in early shared reading behaviors. This will include instructive information for families about using books to stimulate newborns through pictures and spoken words.
Study: NCT00939029

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nicotine replacement therapy (nicotine patches)
Description: 2- 21 mg patches per day for 8 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo NRT
Description: 2 placebo patches (containing no active ingredient)per day for 8 weeks